New pill combo aims to keep breast cancer from returning

NCT ID NCT05780567

Ongoing Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase III trial tests whether adding the experimental drug TQB3616 to standard hormone therapy can help prevent breast cancer from returning in women with HR-positive, HER2-negative breast cancer after surgery. About 1,946 women will receive either TQB3616 or a placebo, plus hormone therapy, for several years. The study tracks how long participants remain cancer-free and monitors side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB3616 (a CDK4/6 inhibitor) combined with endocrine therapy (letrozole, anastrozole, or tamoxifen)
What this could lead to: If successful, this could offer a new option to help prevent breast cancer from coming back after surgery in patients with HR+/HER2- disease.
What could go wrong: This is a Phase III trial, but results are not yet available. The drug may cause side effects and may not prove more effective than current standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, 100021, China
Suining Central Hospital

Suining, Sichuan, 629099, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.